Alumis Financial Statements
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.16+0.19 (+2.73%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alumis revenue and earnings
In fiscal 2025, Alumis generated $24.1 million in revenue. Alumis reported a net loss of $243.3 million, compared with a loss of $294.2 million a year earlier. Operating margin was -1886.9%.
Diluted earnings per share came in at -$2.86.
Summary generated from market data by MetaCap's automated system. Methodology
Alumis income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 24.05M | — | — |
| Revenue growth (YoY) | — | — | — |
| Operating Expenses | 477.85M | 300.75M | 158.17M |
| Research & Development | 386.00M | 265.55M | 137.68M |
| Operating Income | -453.80M | -300.75M | -158.17M |
| Other Income (Expense) | 201.92M | 6.52M | 3.18M |
| Pretax Income | -251.89M | -294.23M | — |
| Income Tax | -8.56M | 0 | 0 |
| Net Income | -243.32M | -294.23M | -154.99M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -2.86 | -10.38 | -72.08 |
| EPS (Diluted) | -2.86 | -10.38 | -72.08 |
| Shares Outstanding (Basic) | 85.03M | 28.34M | 2.15M |
| Shares Outstanding (Diluted) | 85.03M | 28.34M | 2.15M |
| EBITDA | -450.31M | -297.60M | -156.89M |
| Operating Margin | -1886.92% | — | — |
| Net Margin | -1011.75% | — | — |
This table shows 3 annual periods of Alumis's income statement, from FY 2025 back to FY 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ALMS's reporting calendar. What is a income statement?